# Bremelanotide in Premenopausal Women With Female Sexual Arousal Disorder and/or Hypoactive Sexual Desire Disorder

> **NCT01382719** · PHASE2 · COMPLETED · sponsor: **Palatin Technologies, Inc** · enrollment: 612 (actual)

## Conditions studied

- Female Sexual Arousal Disorder
- Hypoactive Sexual Desire Disorder

## Interventions

- **DRUG:** bremelanotide

## Key facts

- **NCT ID:** NCT01382719
- **Lead sponsor:** Palatin Technologies, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-06
- **Primary completion:** 2012-09
- **Final completion:** 2012-09
- **Target enrollment:** 612 (ACTUAL)
- **Last updated:** 2014-12-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01382719

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01382719, "Bremelanotide in Premenopausal Women With Female Sexual Arousal Disorder and/or Hypoactive Sexual Desire Disorder". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01382719. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*